Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate

Annals of the Rheumatic Diseases

Volumn 58, Issue 5, 1999, Pages 281-287

  Sander, Oliver ^a,b   Herborn, Gertraud ^a   Bock, Elisabeth ^a   Rau, Rolf ^a  

^a Department of Rheumatology ^*  (Germany)

^b Evangelisches Fachkrankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; C REACTIVE PROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME;

EID: 0032898755     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.5.281     Document Type: Article

References (50)

1. 1 Morrasut T, Guldstein R, Cyr M, Karsh J, McKendry RJR. Goldsodiumthiomalat compared to low-dose methotrexate in the treatment of rheumatoid arthritis - a randomised double-blind 26-week trial. J Rheumatol 1989;16:302-6.
2. 2 Rau R, Herborn G, Menninger II, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997;36:345-52.
3. 3 Menninger H, Herborn G, Blechschmidt J, Sander O, Rau R. A 36-month comparative trial of methotrexate and goldsodiumthiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 1998;37:1060-8.
4. 4 Rau R, Herborn G, Menninger H, Sangha O. Radiographic progression in early erosive rheumatoid arthritis: 12 month results from a randomised controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998;37:1220-6.
5. 5 Suarez-Almazor MH, Fitzgerald A, Grace M, Russell AS. A randomised controlled trial of parenteral methotrexate compared with sodium aurothiomalate. J Rheumatol 1988; 15:753-6.
6. 6 Kremer JM, Phelps CT. Longterm prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:138-45.
7. 7 Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Longterm prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992;35:129-37.
8. 8 Weinblatt ME, Kaplan H, Germain BF. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol 1991;18:34-8.
9. 9 Sany J, Anaya JM, Lussiez V, Couret M, Clombe B, Davres JP, et al. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 1991;18:1323-7.
10. 10 Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989;28:147-53.
11. 11 Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-9.
12. 12 Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in RA: A 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
13. 13 Pincus T, Brooks RH, Kim YW, Adams RF, Barber J, Barth WF, et al. Methotrexate is continued over five years significantly longer than other second-line drugs in 536 private practice rheumatoid arthritis patients. Arthritis Rheum 1990;33:40.
14. 14 Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-60.
15. 15 Hernandez-García C, Jover JA, Morado IC, Bañares A, Fernández-Gutiérrez B, Macarrón P, et al. Gold salts and methotrexate in daily practice, Short-term safety and efficacy in rheumatoid arthritis. [Abstract]. Arthritis Rheum 1997;40:S51.
16. 16 Keyszer G, Keysser C, Kruse R, Keysser M. The long-term efficacy and safety of disease modifying antirheumatic drugs (DMARD). Results of a meta-analysis of 1681 patients with rheumatoid arthritis (RA). [Abstract]. Arthritis Rheum 1996;39:S106.
17. 17 van Gestel A, Koopman R, Wijnands M, van de Putte L, van Riel P. Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis. J Rheumatol 1994;21:1814-19.
18. 18 Srinivasan R, Miller BL, Paulus HE: Long term chrysiotherapy in rheumatoid arthritis. Arthritis Rheum 1979; 22:105-10.
19. 19 Lockie LM, Smith DM. Forty seven years experience with gold therapy in 1019 rheumatoid arthritis patients. Semin Arthritis Rheum 1985;13:238-46.
20. 20 Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22: 836-43.
21. 21 De La Mata J, Blanco FJ, Gomez Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995;54:881-5.
22. 22 Svensson A, Theander J. Skin rashes and stomatitis due to parenteral treatment of rheumatoid arthritis with sodium aurothiomalate. Ann Rheum Dis 1992;51:326-9.
23. 23 Caspi D, Tishler M, Yaron M. Association between gold induced skin rash and remission in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:730-2.
24. 24 Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
25. 25 Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
26. 26 WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
27. 27 van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PCLM. Development and validation of the European League Against Rheumatism Response Criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
28. 28 Rau R, Wassenberg S, Herborn G, Stucki G, Gebler A. A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol 1998;25:2094-107.
29. 29 Larsen A, Horton J, Howland C. The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis: An x-ray analysis. Clin Rheumatol 1984;3 (suppl 1):97-104.
30. 30 Cats A. Multicentre controlled trial of the effects of different dosage of gold therapy, followed by maintenance dosage. Agents Actions 1976;6:355-63.
31. 31 Luukkainen R, Kajander A, Isomäki H. Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol 1977;6: 189-92.
32. 32 Sigler JW, Bluhm GB, Duncan H, Sharp JT: Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis. A double blind study. Ann Intern Med 1974;80: 21-6.
33. 33 Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973;16:353-8.
34. 34 Buckland-Wright JC, Clarke GS, Walker SR. Erosion number and area progression in the wrists and hands of rheumatoid arthritis patients: a quantitative microfocal radiographic study. Ann Rheum Dis 1989;48:25-9.
35. 35 Buckland-Wright JC. Quantitative microfocal radiography detects changes in erosion area in patients with early erosive rheumatoid arthritis treated with myocrisine. J Rheumatol 1993;20:243-7.
36. 36 Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis. Arthritis Rheum 1982;25:540-9.
37. 37 Munro R, Madhok R, Thomson EA, Capell HA. The degree of functional improvement over 5 years of IM gold depends on initial disease duration. [Abstract]. Arthritis Rheum 1997;10:S52.
38. 38 Roger L, Musi AT, Luther M. High clinical remission rates following early therapy of active rheumatoid arthritis (RA) with aurothioglucose and low-dose triamcinolone. [Abstract]. Arthritis Rheum 1997;40:S51.
39. 39 Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM. Can treatment with methotrexate influence the radiologic progression of rheumatoid arthritis? Clin Rheumatol 1990;9:342-5.
40. 40 Reykdal S, Steinsson K, Sigurjsson K, Brekkan A. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989;18: 221-6.
41. 41 Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. A meta-analysis of treatment termination rates on parenteral gold and methotrexate in rheumatoid arthritis. [Abstract]. Arthritis Rheum 1997;40:S313.
42. 42 The Research Sub-Committee of the Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Report of a multi-centre controlled trial. Ann Rheum Dis 1960;19:95-119.
43. 43 Report of the Research Sub-Committee of the Empire Rheumatism Council: Relations of toxic reactions in gold therapy to improvement in rheumatoid arthritis. Ann Rheum Dis 1961;20:335-40.
44. 44 Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75:69-73.
45. 45 Sander O, Herborn G, Rau R. Flare after discontinuation of "ineffective" disease modifying anti rheumatic drug threatment in active rheumatoid arthritis. [Abstract]. Rheumatology in Europe 1995;24 (suppl 3):226.
46. 46 ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
47. 47 Adams CH, Cecil RL. Gold therapy in early rheumatoid arthritis. Ann Intern Med 1950;33:163-73.
48. 48 Klinkhoff A, Teufel A. The second course of gold. J Rheumatol 1995;22:1655-6.
49. 49 Klinkhoff A, Teufel A. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 1995;22:1657-9.
50. 50 ten Wolde S, Hermans J, Breedveld FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997;56:235-9.